{
    "organizations": [],
    "uuid": "9ea882faced21653a6c7a913aca617513986835c",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-valbiotis-announces-significant-ef/brief-valbiotis-announces-significant-effect-of-valediaon-intestinal-microbiota-idUSFWN1PH03A",
    "ord_in_thread": 0,
    "title": "BRIEF-Valbiotis Announces Significant Effect Of Valedia On Intestinal Microbiota",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 22 (Reuters) - VALBIOTIS SAS:\n* VALBIOTIS ANNOUNCES A SIGNIFICANT EFFECT OF VALEDIA® ON INTESTINAL MICROBIOTA\n* VALEDIA(®) ACTS ON MICROBIOTA IMBALANCES ASSOCIATED WITH METABOLIC DISEASES (PRECLINICAL)\n* ADDITIONAL DATA STRENGTHENS VALUE OF VALEDIA FOR PREVENTING TYPE 2 DIABETES\n* VALBIOTIS CONTINUES ITS METAGENOMICS PROGRAM TO ASSESS HOW ITS PRODUCTS AFFECT MICROBIOTA Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-01-22T15:31:00.000+02:00",
    "crawled": "2018-01-23T18:12:52.011+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "valbiotis",
        "sa",
        "valbiotis",
        "announces",
        "significant",
        "effect",
        "intestinal",
        "microbiota",
        "valedia",
        "act",
        "microbiota",
        "imbalance",
        "associated",
        "metabolic",
        "disease",
        "preclinical",
        "additional",
        "data",
        "strengthens",
        "value",
        "valedia",
        "preventing",
        "type",
        "diabetes",
        "valbiotis",
        "continues",
        "metagenomics",
        "program",
        "assess",
        "product",
        "affect",
        "microbiota",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}